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Braininfarctionduetosmallvesselcerebrovasculardisease(SVCD)—alsoknownassmallvesselinfarct(SVI)or“lacunar”stroke—
accounts for 20% to 25% of all ischemic strokes. Historically, SVIs have been associated with a favorable short-term prognosis.
However, studies over the years have demonstrated that SVCD/SVI is perhaps a more complex and less benign phenomenon than
generally presumed. The currently employed diagnostic and therapeutic strategies are based upon historical and contemporary
perceptions of SVCD/SVI. What is discovered in the future will unmask the true countenance of SVCD/SVI and help furnish more
accurate prognostication schemes and eﬀective treatments for this condition. This paper is an overview of SVCD/SVI with respect
to the discoveries of the past, what is known now, and what will the ongoing investigations evince in the future.
1.Introduction
A 67-year-old man with long history of hypertension (HTN)
presents with a recurrent stroke characterized by acute-onset
left hemisensory loss. He suﬀered his ﬁrst stroke 8 months
ago manifesting as right hemiparesis that resolved over a few
weeks. At that time, he underwent an extensive diagnostic
workup revealing no evidence of craniocervical large vessel
steno-occlusive disease or cardiac abnormalities. A brain
magnetic resonance imaging (MRI) was performed at the
time of the ﬁrst stroke and interpreted by the radiologist as
an acute “lacunar” infarct within the left internal capsules.
He was started on an aspirin and his antihypertensive
medications were “optimized.” His MRI now shows a new
“lacunar” infarct involving the right thalamus (Figure 1).
Dr. Smith, who is the admitting internist, is legitimately
concerned and puzzled by this patient’s stroke recurrence
and consults the neurologist on duty to inquire whether
an increase in the aspirin dose or a “switch” to another
antiplatelet agent is indicated. In addition, Dr. Smith would
also like to know if there is “anything else” that could be
done from a diagnostic viewpoint to direct a more eﬀective
preventative strategy.
The above is a common clinical scenario encountered
by neurologists. Indeed, in the realm of medical decision-
making, these cases are fundamentally perplexing. It is
not simply a conjecture that the patient in the vignette
suﬀers from small vessel cerebrovascular disease (SVCD). As
evidentbyrecurrenceofhisstrokes,hisconditionisprobably
moderate to severe. He presents with a small vessel infarct
(SVI), the typical infarct type associated with SVCD and
historically referred to as a “lacunar” stroke. SVIs account
for 20% to 25% of all ischemic strokes, with an annual
incidence of approximately 15 per 100,000 people [1–3].
Over the past few decades, the preponderance of focus
with regard to acute and preventative stroke therapy has
been placed upon large vessel cerebral ischemia/infarcts.
Subsequently, clinical data strictly pertaining to SVI are
scarce. Although scientiﬁc and technological advancements
have empowered cutting-edge care for stroke patients in2 Stroke Research and Treatment
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Figure 1: Diﬀusion-weighted imaging (DWI) MRI of the brain
showing an acute SVI involving the right thalamus (A) and an older
SVI involving the left internal capsule (B).
general, it appears as though management of SVCD remains
aperpetualtherapeuticconundruminvascularneurology.In
the progressively achieving world of stroke therapeutics, is it
fairtoboldlysuggestthatapathologicalentitydescribedover
50 years ago remains a remedial destitute? In this paper, we
will seek to answer this question by reviewing the past, the
present, and the future of SVCD/SVI.
2. The Past
A “Lacune” (from Lacuna Latin = lake) is a histopathological
nomenclature generated according to what was discovered
in postmortem brain autopsies performed in the 1800s. In
these patients, small ﬂuid-ﬁlled cavities were found in the
deep white matter that resembled small lakes, hence the
term “lacune” (Figure 2). In the 1960s, Fisher conducted
his necropsy series and further acclaimed the term when he
described his ﬁve classic “lacunar” syndromes: pure motor,
pure sensory, ataxic hemiparesis, dysarthria-clumsy hand, and
mixed sensorimotor [4]. Fisher observed that these “lacunes”
were associated with intrinsic small arteriolar abnormalities
that he described as “segmental arteriolar disorganization”
[5]. He then assigned the term lipohyalinosis to this form of
microangiopathy and histologically detailed the ﬁndings as
smallvesselwallthickening, focalarteriolardilatation,lossof
normal vessel wall architecture, and extravasation of blood
components into and through the wall [5]. Based on these
ﬁndings and the clinical correlations he construed, Fisher
certiﬁed his conclusions as the “lacunar hypothesis.”
Over time, additional mechanisms for SVIs were
proposed by Fisher and endorsed by others, includ-
ing an atherosclerotic pathway with a new appellation:
microatheroma [6]. Boiten et al. contended that patients
with “lacunar” infarcts can be placed into two groups: those
with a single “lacune” who primarily have atherosclerotic
risk factors, and those with multiple “lacunes” and a strong
history of HTN [7]. In the end, it was proposed that
both of these mechanisms are consequences of traditional
“lacune”
Figure 2: An illustration of coronal cross section of the brain
showing a small cavity termed a “lacune” within the subcortical
white matter and in the territory of perforating arteries.
vascular risk factors, including and most speciﬁcally HTN
and diabetes mellitus (DM). Other investigators noticed that
notallpatientswithSVIsuﬀerfromHTNandDM.Horowitz
et al. reported that in a cohort of 108 patients with SVI,
HTN was present in 68%, DM in 37%; both occurred in
28% and neither occurred in 23% [8]. They also noticed
that of those without HTN or DM, 32% had a possible
carotid or cardiac etiology. A microembolic hypothesis was
then advanced suggesting that emboli arising from larger
arteriesortheheartcauseocclusionoftheperforatingvessels
andleadtoSVIs[9].Evidencesupportingthishypothesiswas
inlargegatheredfromstudiesinvolvingprimatemodels[10].
The deﬁnition of a “lacunar” infarct is a lesion that is less
than 15mm in diameter in the perfusion territory of a small
penetrating artery [4]. The terms “lacune,” “lacunar infarct,”
and “lacunar syndrome” have been subject of controversy.
Some believe that in a generation where medical eponyms
are gradually becoming obsolete, so should outdated terms.
Designations should be revised so that they are more
descriptive and representative of the pathophysiology of the
condition. In this paper, although SVI and “lacune” will be
used interchangeably, the former is preferred because it is a
ﬁtter depiction of the pathology associated with this stroke
subtype.
3. The Present
3.1. Disease Behavior. SVCD is not a simplistic entity. When
a patient presents with an SVI, it is diﬃcult to determine
how extensive his or her SVCD is. If the patient has evidence
of extensive white matter disease (chronic microvascular
ischemia) or multiple past SVIs on T2/FLAIR MRI, it can be
derived that he or she suﬀers from moderate to severe SVCD
and is at risk for recurrent SVIs (Figure 3). Otherwise, an
angiographic mechanism to deﬁnitively quantify the severity
of SVCD does not exist. Subsequently, one cannot ascertain
whether the patient’s stroke is an isolated event due to a focal
segment of small vessel steno-occlusion or representative of
a more widespread SVCD. Simply said, only the “tip of the
iceberg” may be apparent in our ﬁeld of view. If this is the
case,prognosticationanddeterminationofriskofrecurrence
undeniably become challenging. Over the past few decades,Stroke Research and Treatment 3
Figure 3: Fluid Attenuated Inversion Recovery (FLAIR) MRI of the brain showing extensive SVCD evident by multiple, bihemispheric
subcortical SVIs.
studies aiming to estimate the rate of SVI recurrence have
reported variable ﬁgures. One study reported a ﬁrst-year
recurrence rate of 2.83%, while another study looking at
122 patients with a mean time of 58.3 months between the
ﬁrst ever and the recurrent SVI, reported an 83% rate [11,
12]. A Japanese study, Tottori University Lacunar Infarction
Prognosis Study (TULIPS), followed 885 stroke patients for
1 year after the index event and concluded that SVIs were
associated with the lowest recurrence rate at 6.2% [13].
However, in TULIPS, follow-up period was relatively short
and it is not clear if all patients received maximal therapy.
Regardless of the wavering rates reported in the literature,
at least in the long term, SVIs appear to have a tendency
to recur. Unfortunately, this is sometimes the case despite
optimized stroke preventative therapy.
Soliciting for evidence of prior “silent” or symptomatic
SVIs on brain imaging is certainly helpful in predicting
the risk of recurrence (Figure 3). A prospective study of
175 patients over a median follow-up period of 12 months
found that recurrence rate was 7.7% in patients with a single
SVI and 24.3% in patients with multiple SVIs on brain
imaging [14]. A prior study by De Jong et al. concluded
that prognosis for mortality, recurrent stroke, and overall
functional outcome in “lacunar” stroke patients with one or
more pre-existing silent lesion is less favorable than those
without [6]. It is important to bear in mind that a ﬁrst
SVI may or may not be “silent.” Therefore, an incipient
symptomatic SVI may be the initial glimpse into a more
profound yet arcane cerebrovascular disease, even in the
absence of preexisting lesions.
Based on ongoing investigations, it appears that a much
more complex SVCD/SVI pathophysiology apart from a
simple consequence of HTN and DM may be at large.
The variable behavior of SVCD/SVI from one patient to
another attests to this notion. Although these etiologies
may be exclusive of the traditional vascular risk factors,
they all culminate in a similar morphology of small-
vessel mechanical distortion described by Fisher. Certainly
plausible is a genetic association. How is it that within
a cohort of patients with the same vascular risk factors,
somedeveloplargevesselatherosclerosiswhileothersacquire
SVCD with little evidence of large vessel disease? In the
Northern Manhattan Stroke Study (NOMASS), the preva-
lence of HTN, DM, smoking, and hypercholesterolemia did
not diﬀer between patients with SVI and those with other
stroke subtypes [15]. Is it possible that SVCD is inherited
as a distinct genotypic entity similar to CADASIL (cerebral
autosomal dominant arteriopathy with subcortical infarcts
and leukoencephalopathy) or hereditary forms of cerebral
amyloid angiopathy (CAA)?
A recent study showed that family history of stroke
might be an independent risk factor for the SVI phenotype
with asymptomatic SVIs at a younger age [16]. This study,
however, regarded a family history of stroke in a broad
sense, not delineating the subtype of the stroke in family
members. In an Australian cohort, Jannes et al. reported
that polymorphism in the tissue plasminogen activator
(tPA) gene (−7351C/T) was a risk factor for SVIs, but
n o to t h e rs t r o k es u b t y p e s[ 17]. Other associations have
been reported including polymorphism of the angiotensin
converting enzyme (ACE) and interleukin-6 (IL-6) genes
[18, 19]. These studies represent important evidence for a
genetic connection and suggest that SVI might result from
genetic susceptibility to inﬂammation-mediated injury in
conjunction with atherosclerotic risk factors [20].
Fisher implied in 1969 that “lacunar” infarcts were
associated with a relatively good prognosis. Perhaps he
anticipated and hoped that novel therapies for SVCD were
in the horizon. Considering merely the size of a single,
isolated SVI, it may be true that these strokes bear a more
favorable prognosis for recovery than other stroke subtypes
[21]. However, their natural history may not be as benign
as commonly presumed. In a recent study of patients aged
55–85 years with a 12-year follow-up period, the acute index
strokeattributabletoSVCDwasassociatedwithpoorerlong-
term survival and higher risk for cardiac death than other
stroke subtypes [22]. The “good prognosis” presumably
associated with SVIs is only the case early in the disease
course. Years after the infarct, there is an increased risk of
death, mainly from cardiovascular causes [23]. Additionally,4 Stroke Research and Treatment
the cumulative eﬀect of recurrent SVIs needs to be consid-
ered. As the patient suﬀers additional SVIs—even in form
of “silent” strokes—coalescence and the additive impact of
these infarcts may eventually lead to signiﬁcant physical dis-
ability manifested by gait apraxia, urinary incontinence, sub-
cortical vascular dementia, emotional lability/incontinence
(pseudobulbar palsy), and aﬀective disorders. SVI caused
by SVCD is a major cause of progressive motor deﬁcits
[24]. Predictors of mortality after the ﬁrst-ever SVI are age,
degree of neurological dysfunction, and functional disability
at day 7 [25]. It is, therefore, imperative that clinicians regard
SVCD/SVI as a progressively debilitating condition often
characterized by delayed, irreversible consequences.
3.2. Therapeutic Inquest. It has been understood for decades
that optimal management of HTN and DM theoretically
prevents the progression SVCD and thereby, the recurrence
of SVIs. Does this therapeutic endeavor reverse the already
progressed disease? What is the “optimal” therapy for
secondary SVI prevention beyond HTN and DM control?
There has been mounting evidence that SVIs are diﬀerent
than large vessel (or “nonlacunar”) infarcts with respect to
pathophysiology, etiology, and prognosis. In spite of this, the
current American Heart Association’s (AHA) Guidelines for
the Prevention of Stroke in Patients with Stroke or Transient
Ischemic Attack do not diﬀerentiate between the two with
regard to therapy and preventative measures [26]. Does this
“one size ﬁts all” policy apply to SVCD/SVI?
3.2.1. Antiplatelet Agents. The earlier clinical trials looking
at the role of antiplatelet agents and anticoagulants clearly
demonstrated the beneﬁt of these medications in general
secondary prevention of strokes [27, 28]. These studies did
not exclusively look at SVIs, and therefore data speciﬁc to
this stroke subtype are scarce. For years, the cornerstone
of SVI prevention has been control of HTN and DM.
Antiplatelet agents are prescribed for SVI patients as a
part of a general stroke prevention regimen. However,
some neurologists believe that antiplatelet agents are not
necessarily of enormous beneﬁt in SVCD and focus should
be placed strictly on eﬀectively treating HTN and DM.
Because of ethical implications, it is impossible to conduct a
clinical trial comparing an antiplatelet agent against placebo
insecondarySVIprevention.However,onestudydidexplore
that and reported intriguing results. The Cilostazol Stroke
Prevention Study (CSPS) was a multicenter, randomized,
placebo-controlled, double-blind clinical trial examining the
eﬀects of cilostazol on the recurrence of cerebral infarction
[29]. Cilostazol is an antiplatelet agent that increases the
cyclic adenosine monophosphate levels in platelets via
inhibition of phosphodiesterase. Cilostazol was found to
reduce the risk of secondary stroke by 41.7% compared
with placebo. CSPS investigators reported that the greatest
risk reduction was found in patients who initially had a
“lacunar” infarction (43.4% in cilostazol versus placebo, P =
0.0373), suggesting that cilostazol has a speciﬁc eﬀect against
SVCD. However, it is important to allude to the fact that
close to 75% of patients in each arm had an SVI as the
initial event. This unequal distribution of patient population
could have created a bias with respect to the results, yet it
demonstrated clearly that antiplatelet agents are not futile in
secondary prevention of SVIs. A subsequent CSPS-2 study
demonstrated the noninferiority of cilostazol to aspirin, but
the focus was general stroke prevention and not speciﬁc to
SVIs [30]. In conclusion, antiplatelet agents are indicated in
SVCD for prevention of SVIs. The reason why a patient has a
subsequent SVI on an antiplatelet agent is possibly due to the
recurrentnatureofSVIsandnotnecessarilyaconsequenceof
medication failure.
3.2.2. Statins. The AHA Guidelines also do not address
the utility of 3-hydroxy-3-methyl-glutaryl-CoA reductase
inhibitors (HMG-CoA RI) or “statins” speciﬁcally in sec-
ondary prevention of SVIs. As for general stroke prevention,
the Guidelines recommend “intensive lipid-lowering” to
reduce risk of stroke and cardiovascular events among
patients with ischemic stroke or transient ischemic attack
(TIA) who have evidence of atherosclerosis or a low-density
lipoprotein C (LDL-C) level ≥100mg/dL [26]. Although the
use of statins in treatment of patients with cerebrovascular
disease was initially approved by the Food and Drug
Administration (FDA) in the wake of the Heart Protection
Study, this particular recommendation is largely based on
the Stroke Prevention by Aggressive Cholesterol Lowering
(SPARCL) study [31, 32]. SPARCL showed a ﬁve-year abso-
lute risk reduction of 2.2% (P = 0.03) for recurrent strokes
with administration of high-dose (80mg) atorvastatin as
compared with placebo. Patients with SVI as entry event
were included in the study. With a number-needed-to-treat
(NNT) of 258 to prevent a ﬁrst recurrent stroke over one
year, many question the ostentatious results of SPARCL.
Furthermore, there exists a degree of hesitance among some
neurologists to treat SVCD patients with high-dose statins
because of risk of intracerebral hemorrhage (ICH). There
is some evidence suggesting that patients with SVCD may
suﬀer chronic “silent” cerebral microhemorrhages that could
potentially convert to larger hemorrhagic foci or frank
ICH[33].Nonetheless,SPARCLinvestigatorscontendedthat
subjects with SVI at baseline who were treated with high-
dosestatinshadabeneﬁtintheprimaryendpoint(combined
risk of any fatal or nonfatal stroke) that was almost identical
to the beneﬁt in the overall study population, with no overall
treatment-related diﬀerence in the frequency of fatal ICH
[34]. Indeed, there was an increased rate of ICH in patients
with SVCD and SVI at entry who underwent intensive
treatmentwithstatins(HR,4.99;95%CI,1.71to14.61)[34].
However, the authors maintained that the data sustaining
this ﬁnding lacked statistical validity because of a high
tendency towards false positives [34]. Another study of 94
SVI patients treated with 80mg of atorvastatin per day did
not improve severe cerebral vasoreactivity and microvascular
endothelial dysfunction assessed by ultrasonographic tech-
nology [35]. Given these ﬁndings, implementation of statins
at high doses in SVCD/SVI patients remains controversial. It
is yet to be determined whether the overall beneﬁt of high-
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higher risk of ICH. Perhaps higher prevalence of HTN in
patient with SVCD/SVI plays a contributing role to this risk.
3.2.3. Intravenous Thrombolytics. The National Institutes of
Neurological Disorders and Stroke (NINDS) thrombolytic
trial reported that all stroke subtypes, including SVIs,
responded favorably to intravenous (IV) recombinant tissue
plasminogen activator (rtPA) [36]. Some experts argue
against this notion. In his textbook entitled Stroke, Caplan
expresses his skepticism regarding the beneﬁt of IV rtPA
i nS V I s .H er a i s e ss e v e r a lp i t f a l l si nt h eN I N D Sr t P At r i a l
including, less-than-thorough examinations by the inves-
tigators, inadequate brain imaging, and dissimilar subject
numbers between the treatment and the placebo groups
[37]. Caplan further asserts that a committee designated
to conduct post hoc analysis of the NINDS rtPA data
later suggested that the trial’s conclusions pertaining to
stroke subtypes were invalid [38]. Until further data is
available, there is no evidence suggesting that IV rtPA is
of dubious beneﬁt in acute SVI. Therefore, IV rtPA should
not be withheld based upon anecdotal declarations, since
it remains the only acute therapeutic option in acute SVI.
Additionally, It is not always possible to clinically link a
“lacunar syndrome,” such as pure motor paresis, to an SVI.
A non-SVI mechanism is responsible for 25% of cases that
present with a “lacunar syndrome.” [15]. If we decide to
withhold administration of IV rtPA purely based on clinical
grounds (lacunar hypothesis), we could theoretically deprive
of treatment 1 out of every 4 patients presenting with a so-
called “lacunar syndrome.”
3.2.4. CarotidSurgery. One challenging scenario is whenone
encounters a patient with an SVI and an ipsilateral internal
carotid artery (ICA) stenosis. Would this be considered a
“symptomatic” ICA stenosis and should this patient undergo
carotid endarterectomy (CEA)? Recall that animal models
have corroborated the embolic theory for occurrence of SVIs
in the face of an ipsilateral ICA disease [10]. In a sub-
group analysis, the North American Symptomatic Carotid
Endarterectomy Trial (NASCET) group reported that SVIs
occurred more often with milder (<50%) ICA stenosis, and
forpatientswith50%to99%stenosis,therelativeriskreduc-
tions in stroke from CEA were 35% and 61% for probable
SVI and non-SVI, respectively [39]. The European Carotid
SurgeryTrialists(ECST)alsofoundthatSVIswereassociated
with milder cases of ICA stenosis, but maintained that small
numbers did not allow conclusive evidence on the eﬃcacy
of CEA in SVI patients with severe stenosis [40]. The ECST
investigators,therefore,concludedthatsevereICAstenosisin
SVI patients is usually incidental, and so should be deemed
“asymptomatic.” Tejada et al. found signiﬁcant incidence
of isolated ipsilateral ICA stenosis in patients with SVIs in
the ICA territory, particularly ipsilateral multiple SVIs [41].
The authors suggested a signiﬁcant relationship between the
pattern of distribution of SVIs in only one hemisphere and
ipsilateral ICA stenosis more than 70% (OR, 4.4; 95% CI,
0.9 to 19; P = 0.03). Unfortunately, the evidence supporting
one approach over the other is lacking due to nebulous,
conﬂicting information. Cases could range in complexity
from multiple SVIs in the territory of a severely stenotic ICA
(andapaucityofSVIswithinotherterritories)toastenosisin
the 50% to 69% range and a solitary SVI within its perfusion
domain. There is some data suggesting that in patients with
moderate ICA stenosis, distinctive ultrasonographic ﬁndings
(intima-media thickness and cerebrovascular reactivity to
hypercapnea) could assist in diﬀerentiating between an SVI
due to ICA disease and otherwise [42]. Further studies are
certainly required to clarify this. Ultimately, careful workup
and decision-making needs to take place on a case-by-
case basis, bearing in mind individual factors such as age,
comorbid conditions, and of course, institutional rates of
perioperative complications.
4. The Future
The future of SVCD/SVI is contingent upon two main
aspects: accurate prognostication and eﬀective management.
Autopsy-centered investigations such as those conducted by
Fisherarenoteasytocarryoutbecauseofthelowcasefatality
of SVIs [43]. Moreover, histopathological data obtained
from these investigations may not provide any additional
information with regard to pathophysiology and natural
history of the disease. This is unless the intention is to utilize
sophisticated staining techniques to discover accumulation
within the vessel wall of pathological polypeptides similar to
amyloid in CAA or Notch-3 protein in CADASIL.
Prognostication of SVCD/SVI requires the ability to
predict the risk of recurrence. If one discounts the unequal
follow-up durations between studies, the variable reported
recurrence rates could be attributed to a few possible
theories. First, multiple etiologic and pathophysiological
mechanismsmaybeimplicatedinthedevelopmentofSVCD,
all inherently associated with occurrence of SVIs. Again,
these mechanisms may be completely exclusive of HTN
and DM, or emboldened by them. Explorative endeavors
should focus on biological and inﬂammatory markers that
may be more prevalent in patients with SVCD/SVI and
potentially amenable to modiﬁcation and/or therapy. As an
example, a recent study determined that in patients with
more than one small vessel lesion or extensive white matter
disease on brain MRI, there were higher levels of serum tPA
and lower levels of plasminogen activator inhibitor type 1
(PAI-1) when compared with patients with a solitary SVI
[44]. The authors postulated that diﬀerences in activity of
components of the ﬁbrinolytic system might be involved
in the pathophysiology of SVCD. There is also evidence
that implicates chronic endothelial dysfunction assessed
by measuring circulating levels of intercellular adhesion
molecule 1 (ICAM-1), thrombomodulin (TM), tissue factor
(TF), and tissue factor pathway inhibitor (TFPI) [45].
Another study showed that, after adjustment for potential
confounders, serum tumor necrosis factor-alpha (TNF-
alpha) >14pg/mL and ICAM-1 >208pg/mL were indepen-
dently associated with early neurological deterioration and
poor outcome at 3 months in patients with SVI [46]. Also,
monocyte count might be an inﬂammatory risk marker6 Stroke Research and Treatment
for development of SVIs [47]. The Levels of Inﬂammatory
Markers in the Treatment of Stroke (LIMITS) in an ongoing
prospective,observationalstudyaimedtodetermineifserum
levels of inﬂammatory markers—such as high-sensitivity c-
reactive protein (hsCRP), serum amyloid A (SAA), CD40
ligand (CD40L), and monocyte chemoattractant protein-
1 (MCP-1)—predict recurrent stroke and other vascular
events among people with a history of SVI [48]. These
biologicalandinﬂammatorymarkerscouldserveaspotential
therapeutic targets in the future.
Second, SVCD may be a unique genetic disorder or
set of disorders with variable penetrance or expressivity
and subsequently with diverse phenotypic severity. Several
distinct genes could be involved in the pathophysiology of
SVCD. Individual genetic factors may perhaps predispose to
speciﬁc stroke subtypes only, and not to strokes overall [49].
Exploring these concepts requires long-term, longitudinal
investigation of patient pedigrees with speciﬁcation of stroke
subtypes in family members. The Siblings with Ischemic
Stroke Study (SWISS) is a multicenter, observational study
of sibling pairs and is determined to identify regions of
the human genome that correlate with risk of developing
ischemic stroke [50]. This study conducts genome-wide
screen using DNA obtained from concordant and discordant
sibling pairs. Although the SWISS investigators are not
conducting subtype analysis (yet), subjects with SVI are
included. Once completed, future assays of SWISS could
provide an insight into the genetics of SVIs.
Third,theinitialSVImaybeduetoeitherafocal,isolated
small vessel stenosis or a reﬂection of a more capacious
disease. As previously mentioned, angiography is of limited
use with respect to precisely gauging the severity of SVCD.
However, brain perfusion studies could be useful in that
regard. Computed tomographic perfusion- (CTP-) derived
subcortical white matter cerebral blood ﬂow (CBF) has been
shown to be independently associated with white matter
disease severity [51]. It is known that greater white matter
disease burden is associated with SVI compared with other
ischemic stroke subtypes and therefore a marker of more
severe SVCD [52]. But does an MRI devoid of extensive
whitematterdiseasecompletelyruleoutsevereSVCD?Com-
parison of postmortem MRI and histopathology suggests
the existence of “MRI invisible” SVCD [53]. Quantitative
MRI techniques, such as diﬀusion tensor imaging, may
help unmask SVCD otherwise undetectable on conventional
MRI [53]. Although such sophisticated imaging modalities
may not be widely available, prospective research utilizing
this technology could provide additional angles for accurate
prognostication of SVCD in the years to come.
All of the possibilities mentioned above inﬂuence our
ability to proximately predict prognosis. They also con-
tribute to the prospect of ﬁnding more eﬀective therapies
for SVCD/SVI. Closer acumen into the causes of SVCD
in advance of HTN and DM can help direct etiology-
tailoredtreatments.However,untilnoveltherapeuticoptions
emerge,neurologistsarelimitedtoonlythemedicalremedies
that are available at present. Hence, the initial step in
the therapeutic inquest for SVCD/SVI is optimization of
current therapies. There is a paucity of data with regard
to optimal blood pressure, serum glucose, and choice of
medications in secondary prevention of SVIs. In Prevention
Regimen For Eﬀectively avoiding Second Strokes (PRoFESS)
where more than 50% of the patients had suﬀered an
SVI as the index event, there was no diﬀerence between
clopidogrel and aspirin/extended-release dipyridamole with
regard to eﬀectiveness in prevention of recurrent strokes
[54]. In another arm of PRoFESS, it was demonstrated
that treatment with telmisartan (an angiotensin receptor
blocking agent) initiated soon after an ischemic stroke
and continued for 2.5 years did not signiﬁcantly lower
the rate of recurrent stroke [55]. The Study of Prevention
of Small Subcortical Strokes (SPS3) is an investigational
eﬀort seeking to address the optimal therapy for patients
with SVI and is expected completion in spring of 2012
[56]. In SPS3, eligible SVI patients are randomized in a
double-blind fashion to receive either aspirin 325mg/day
or a combination of aspirin 325mg/day and clopidogrel
75mg/day. Hypertensive SVI patients are randomized to
receive antihypertensive therapy with a target systolic blood
pressure of either <150mmHg or <130mmHg. Primary
outcomes measures are recurrent stroke, major vascular
events, or cognitive decline. ICH, systemic hemorrhage,
and side eﬀects of aggressive antihypertensive therapy are
designated as secondary outcome measures. LIMITS and
SPS3 employ the same pool of subjects to determine if
inﬂammatory markers predict which people will respond
best to dual antiplatelet therapy (clopidogrel and aspirin).
As recommended by the study’s Data and Safety Monitoring
Board, the National Institute of Neurological Disorders and
Stroke (NINDS) stopped the antiplatelet component of the
study due to an increased rate of major hemorrhage and
death in patients receiving combination antiplatelet therapy.
Moreover, a futility analysis demonstrated little likelihood
of beneﬁt in favor of aspirin plus clopidogrel on recurrent
stroke should the study continue to conclusion. The blood
pressure intervention component of the study was allowed to
continue.
Other investigative approaches to deﬁne more precise
therapies could involve comparing various antihypertensive
or antihyperglycemic medications in an aim to determine
the ideal class of agents for SVI prevention. In closure,
experimental therapeutic studies involving patients with
SVCD/SVI are much needed.
5. Conclusion
The issues raised above encourage taking a broader view in
diagnosisandmanagementofSVCD/SVI.Manyofthepoints
discussed have been widely known for years and continue to
challenge the minds of neurologists and clinicians alike. It
is gradually becoming apparent that SVCD/SVI is a much
more complex phenomenon than what was described by
Fisher decades ago. The “optimal” treatment with regard to
prevention of secondary SVIs is still at its minimum. Simply
suggesting maximal control of HTN and DM as the ideal
therapy and switching back-and-forth between antiplatelet
agents are becoming self-fulﬁlling strategies. Perhaps theStroke Research and Treatment 7
time has arrived that we diligently look beyond Fisher’s
“lacunar hypothesis” and seek further explanations as to why
SVCD so peculiarly behaves the way it does.
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